Depression treatment for Pompano Beach — the full escalation pathway, 28 minutes away.

Pompano Beach clients drive 18 miles up I-95, about 28 minutes, to reach a psychiatrist-led outpatient program that runs SSRI and SNRI trials to adequate dose and duration, then names TMS or Spravato at trial two rather than trial five. Every plan is built on a DSM-5-TR diagnosis, a baseline PHQ-9, and a written escalation pathway. In-network with the major Florida commercial plans, and structured to catch the bipolar, thyroid, and substance-use mimics primary care rarely rules out.

From Pompano Beach up to RECO Integrated Psychiatry’s Delray Beach office is 18 miles on I-95 — roughly 28 minutes outside rush hour, and a clean clinical break from Cresthaven, Lighthouse Point, Sea Ranch Lakes, and Hillsboro Shores without leaving the South Florida corridor. Pompano clients arrive for a specialist-level outpatient workup: a documented DSM-5-TR diagnosis, a baseline PHQ-9, and a written medication and escalation plan rather than another open-ended refill. Every case — from a first-episode presentation to a treatment-resistant depression with four prior failed trials — is worked through the same algorithm.

The diagnostic questions primary care doesn’t ask

Before any prescription is written for a Pompano Beach client presenting with low mood, the psychiatrist screens for bipolar spectrum illness using the MDQ and, where indicated, the HCL-32, and takes a detailed mood history covering prior hypomanic periods, family psychiatric history, age of onset, and postpartum episodes. This matters because antidepressant monotherapy in an unrecognized bipolar II presentation reliably induces mixed states, rapid cycling, and iatrogenic worsening — and it is one of the most common preventable errors in outpatient depression care.

The intake also rules out the medical and psychiatric mimics that primary care visits rarely have time for: TSH and free T4 for thyroid dysfunction, a substance use inventory that distinguishes alcohol-driven mood collapse from primary depression, and structured screens for undertreated OCD (YBOCS), PTSD, ADHD (ASRS), and generalized anxiety (GAD-7). When the underlying disorder is OCD or PTSD, layering another SSRI on top of an untreated primary diagnosis is not a treatment — it is a delay.

Chronic sleep restriction, uncontrolled sleep apnea, and low-grade alcohol use are cataloged at intake rather than deferred to visit four. The initial evaluation is 60 to 90 minutes precisely so that these questions get asked once, thoroughly, at the beginning.

First-line pharmacotherapy done well

For an uncomplicated depression treatment case, first-line pharmacotherapy is an SSRI — sertraline, escitalopram, or fluoxetine — or an SNRI where pain, fatigue, or comorbid anxiety point that direction, typically venlafaxine XR or duloxetine. The medication is started at a documented starting dose, titrated to a therapeutic dose within two to four weeks, and given a full six-to-eight-week trial at that dose before response is judged. PHQ-9 is repeated at each visit; response is defined as a 50% reduction, remission as a score under 5.

Bupropion is the first-line choice where sexual side effects, sedation, or weight gain would derail adherence, and it is often the right answer for high-functioning professionals commuting from Lighthouse Point who cannot tolerate SSRI-associated anergia. Mirtazapine is reserved for insomnia-predominant, appetite-suppressed presentations where a sedating antidepressant does double duty. The two variables insurance requires later — adequate dose and adequate duration — are documented from day one so the escalation pathway is not blocked by an incomplete chart.

Augmentation and switching after partial response

Partial responders — clients whose PHQ-9 drops meaningfully but not into remission — are augmented before they are switched. First-line augmentation choices with the strongest randomized-trial evidence are aripiprazole (2 to 15 mg), lithium titrated to a level of 0.4 to 0.8 mEq/L for augmentation, and T3 at 25 to 50 mcg. Bupropion augmentation is used for residual anergia, low motivation, and cognitive slowing. Quetiapine XR is reserved for depression with prominent sleep disruption or anxious distress.

For non-responders — a PHQ-9 that has not moved after an adequate trial — a within-class SSRI-to-SSRI switch has limited evidence and is typically skipped in favor of a cross-class change: SSRI to SNRI, SSRI to bupropion, or SNRI to a novel-mechanism agent. Every switch is planned with a documented rationale, taper schedule, and washout where required. Adjunctive CBT or behavioral activation is recommended in parallel; ACT and MI are integrated for clients whose depression is tangled with values conflict or ambivalence about behavior change.

The interventional escalation pathway

After two adequate antidepressant trials at adequate dose and duration, a client meets the standard definition of treatment-resistant depression — and, importantly, meets coverage criteria for TMS and Spravato under most commercial plans. RECO Integrated Psychiatry names the interventional option at trial two rather than at trial four or five, which is where most scattered outpatient histories stall.

Repetitive TMS is offered on a standard protocol — 3000 pulses per session at 120% of motor threshold to the left dorsolateral prefrontal cortex, five sessions per week for six weeks, followed by a taper — for clients who prefer a non-medication interventional option and can commit to the daily schedule. Spravato (esketamine) is offered on-site under REMS monitoring for clients who need a rapid-response option or who have failed TMS. IV ketamine is available as a cash-pay pathway for clients on a compressed timeline. The escalation is planned at intake and revisited at each medication decision point, not improvised after the fifth failed SSRI.

What to expect on your first visit

The initial evaluation is 60 to 90 minutes with a board-certified psychiatrist. Clients complete PHQ-9, GAD-7, MDQ, and ASRS in advance; the visit itself covers current symptoms, prior medication history with specific doses and durations, medical comorbidities, substance use, family history, and safety assessment. A working diagnosis, initial treatment plan, and the escalation branch points are documented before the client leaves.

Follow-up cadence is typically every two weeks during titration, then every four to six weeks in maintenance. Telepsychiatry follow-ups are available for clients whose Pompano Beach schedule doesn’t accommodate a 28-minute drive every visit, though initial evaluations and controlled-substance visits are conducted in person.

Insurance and admissions from Pompano Beach

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. TMS and Spravato are covered under most commercial plans once treatment-resistance criteria are documented; the admissions team runs a benefits check and handles the prior authorization before the first interventional session is scheduled. Cash-pay rates are published for clients who prefer to keep depression care off insurance for confidentiality reasons — a common request from Pompano professionals in licensed or credentialed roles.

Common comorbidities managed in the same clinic

• Anxiety disorders: GAD-7-guided treatment with SSRI/SNRI plus CBT; buspirone augmentation where SSRI response is partial.
• ADHD: ASRS-guided workup, stimulant or non-stimulant trial, with depression stabilized first.
• OCD: YBOCS-guided high-dose SSRI plus exposure and response prevention.
• PTSD: EMDR or trauma-focused CBT alongside SSRI or prazosin for nightmares.
• Alcohol use disorder: Naltrexone or acamprosate, with depression treatment sequenced appropriately.

Serving residents of: Cresthaven, Lighthouse Point, Sea Ranch Lakes, Hillsboro Shores.